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Health-related quality of life is associated
with arterial PO2 in chronic obstructive
pulmonary disease
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Insensitive lung-specific questionnaires may explain the poor association between arterial PO2 and reported health-
related quality of life. Conceivably, modern lung specific or generic quality of life measures might show a better
association with arterial PO2.
Fifty-nine outpatients (34 men) with chronic obstructive pulmonary disease (COPD) who fulfilled the following
criteria were studied: age 18–67 years, FEV1  70%,  15% reversibility after b2-agonist inhalation, and no other
disabling disorders. All completed the Respiratory Quality of Life Questionnaire (RQLQ) and Short Form 36 (SF-
36), and were tested with spirometry and arterial blood gases. In accordance with available COPD staging systems,
patients were divided into those with an FEV1 of 550% and 50–70% of predicted.
Patients’ characteristics were, [mean (SD)]: age: 57?0 years (9.0); FEV1: 1?46 (0?6). Spearman’s rank correlations
between arterial PO2 and dimensions of the RQLQ ranged from 0?25–0?52, and were greater than for the SF-36
(0?14–0?36) in patients with moderate to severe COPD.
The association between arterial PO2 and quality of life scores in moderately to severely aected COPD patients
was moderate, but higher than previously reported. The associations were higher with a lung-specific questionnaire
than with a general health measure, indicating a higher sensitivity of the lung-specific measure in this patient group.
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Patients with advanced chronic obstructive pulmonary
disease (COPD) are often severely incapacitated by breath-
lessness and impairment in physical, cognitive or mental
function, having a reduced quality of life. Previous studies
have shown good association between dimensions of
HRQL, exercise capacity and dyspnoea, but not with
spirometry and PaO2 (1–4), although a recent study found a
moderate association between dimensions of HRQL and
groups of patients categorized after FEV1 in % of predicted
(5). These clinical indicators of disease severity are also
associated with each other (6).
Chronic hypoxia in advanced COPD can lead to
cyanosis, polycythaemia, and symptoms of drowsiness,
fatigue and disturbed mental function. Hence, we think it
is strange that a considerable reduction in lung function
with hypoxia is not associated with lower HRQL scores.Received 27 September 1999 and accepted in revised form 2 March
2000.
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0954-6111/00/080772+06 $35?00/0Conceivably, HRQL instruments used so far may have been
insuciently sensitive to detect such an association (274).
A higher association between degree of hypoxaemia and
HRQL scores was found when a lung-specific questionnaire
was compared with a generic questionnaire in outpatients
with COPD and FEV1 5 1?51 (7). The arterialized earlobe
technique used for assessing PaO2 has, however, been
criticized (8).
We hypothesized an association between arterial PaO2
and HRQL: patients with hypoxia seem to have a poorer
HRQL, and a more lung-specific HRQL might show a
greater association. For assessing HRQL, we used a short
lung-specific health status measure, a modification for
COPD of the 20 item Australian AQLQ (9), and a 36 item
general health measure SF-36 (10) in outpatients with




All 198 outpatient clinic patients aged 18–67 years with an
ICD-9 code of 496 seen at the Central Hospital of Akershus# 2000 HARCOURT PUBLISHERS LTD
HEALTH-RELATED QUALITY OF LIFE AND COPD 773from 1 January 1994 to 10 April 1995 were scrutinized for
eligibility in the study. Seventy-seven fulfilled the following
inclusion criteria: FEV1  70% of predicted,  15%
improvement in FEV1 after inhalation of b2-agonist, and
absence of ischaemic coronary disease, intermittent claudi-
cation and musculoskeletal and various disabling disorders.
Patients were classified according to COPD disease
severity, as recommended by the American Thoracic
Society (ATS) (11) and the European Respiratory Society
(ERS) (12):
Group 1: (moderate to severe disease); patients with FEV1
5 50 percent of predicted value by height and age (ATS
stage II-III and ERS stage III), and
Group 2: (mild disease); patients with FEV1 50–70
percent of predicted value (ATS stage I; ERS stage II).
STUDY DESIGN
Self-administered questionnaires were filled in at home the
day before an outpatient consultation, during which all
had: (i) a thorough pulmonary function testing, and (ii) an
arterial blood gas analysis. The sequence of questionnaires
was the same throughout the study.
PULMONARY FUNCTION TESTING
FEV1 and FVC were determined using a pneumotacho-
graph (Jaeger, Wu¨rzburg, Germany). All patients were
instructed not to take b2-agonists in the morning that day,
nor inhalers during the last 4 h before testing. All lung
function tests were administered by the same experienced
technician. European Community for Coal and Steel values
were used as reference (13).
Blood was drawn from the radial artery at the wrist for
analysis of PaO2 and PaCO2 (ABL 520 blood gas analyzer,
Radiometer, Copenhagen, Denmark).
HEALTH-RELATED QUALITY OF LIFE
ASSESSMENT
Respiratory Quality of Life Questionnaire (RQLQ)
We used a modification of the self-administered Australian
Asthma Quality of Life Questionnaire (9,14), consisting of
20 items scored on a 5 point Likert scale. Scores are
aggregated to a total score and four subscales: breath-
lessness, mood, concerns and social. Scores range from
0 (least problems) to 10 (most problems or symptoms).
This instrument is brief and easy to score (9) and has
previously been used in Australia, Spain, the U.K. (9,14,15)
and, the modified questionnaire, in Norway (16). The
reliability and validity of the RQLQ has been confirmed in
COPD patients (16).Short Form 36 (SF-36)
The general health status questionnaire SF-36 intends to
assess aspects of health important to all patients. SF-36 was
developed in the U.S.A., contains eight scales (10,17) and
two component summary scales, and has been extensively
validated, although with limited experience in COPD. The
Norwegian standard version 1?0 as translated in the
IQOLA project (18,19) was used, assessing health status
during the past 4 weeks.
DATA ANALYSIS
Mann–Whitney U-test was used for comparison of baseline
spirometry values for participants and non-participants.
Mann–Whitney U-test or w2 test was used for comparison
of patient characteristics and HRQL scores between
groups. We used Spearman’s rank correlation for assessing
correlations between quality of life measures and lung
function. Correlations were labelled as: fair (0?21–0?40),
moderate (0?41–0?60) or substantial (0?61–0?80) (20).
In a multiple linear regression model, we assessed the
association between PaO2 and global HRQL (RQLQ total)
after adjusting for age and gender in the patient group
with moderate/severe COPD. This dimension is an aggre-
gate of 20 items and was close to normally distributed.
Because of the limited sample size, we could not justify
including more than three independent variables in the
model (21). We chose to adjust for age and gender, since
these variables are considered important confounding
variables in epidemiology, and they are well known to
influence HRQL (10,19).
The statistical software SPSS for windows was used for
all statistical analyses (SPSS Inc, Chigaco, IL, U.S.A). The
study was approved by the regional medical ethics review
committee.
Results
Of 77 eligible patients, six could not be reached, seven
refused to participate, and five finally withdrew after
initially giving their consent, hence 59 (34 men and 25
women) individually completed the study. According to
data from the qualifying, previous clinical visit, the
participants (n=59) had significantly better spirometry
values before inclusion than non-participants (n=18), mean
FEV1 (%pred)=52?2 and 39?8 respectively; P=0?002. Age
was similar for the two groups. Patients in the moderate to
severe group, FEV1 (%pred) 550, were older and had
poorer FVC and FEV1/FVC ratios than patients in the
group with mild disease, FEV1 (%pred) 50–70 (Table 1).
However, there were no dierences between the groups in
gender composition, PaO2, PaCO2 and SaO2 (Table 1).
Spearman’s rank correlations between HRQL and PaO2,
and PaCO2 indicated a greater correlation between PaO2 and
HRQL for most dimensions of the lung-specific measure
RQLQ than for the general health measure SF-36 in
moderate/severe COPD (Table 2). Plots of PaO2 and the
RQLQ dimensions in the moderate/severe group, where
TABLE 1. Characteristics and physiological variables for study patients
Total sample Moderate/severe




No. of patients (M:F) 59 34 25
Gender (M:F) (34:25) (18:16) (16:9) NS{
Age 57?0 (9?0) 60?0 (5?8) 52?9 (11?0) 0?002
FEV1 (1) 1?46 (0?6) 1?04 (0?35) 2?03 (0?52) 50?001
FEV1 (%pred) 47?1 (15?3) 36?2 (8?2) 62?0 (8?4) 50?001
FEC (1) 3?05 (1?1) 2?56 (0?91) 3?71 (1?01) 50?001
FEC (%pred) 79?8 (17?4) 71?2 (15?2) 91?6 (12?9) 50?001
FEV1/FVC (%) 47?6 (10?1) 41?7 (7?4) 55?5 (7?4) 50?001
PaO2 (kPa) 9?3 (1?4) 9?20 (1?43) 9?56 (1?28) NS
PaCO2 (kPA) 5?0 (0?52) 4?98 (0?61) 5?15 (0?33) NS
SaO2 (%) 95?7 (2?5) 95?2 (2?8) 96?4 (1?98) NS
Values are mean (SD); NS; not significant; *moderate/severe vs. mild disease, Mann–Whitney U-test; { w2-test.







Measure PaO2 PaCO2 PaO2 PaCO2 PaO2 PaCO2
RQLQ
Breathlessness 70?16 70?23 70?25 70?25 0?04 70?06
Concerns 70?28* 70?23 70?52{ 70?11 0?15 70?19
Mood 70?20 0?02 70?45{ 0?01 0?15 70?01
Social 70?23 70?31* 70?47{ 70?26 0?18 70?17
Total 70?27 70?19 70?43* 70?11 0?12 70?15
SF-36
Physical functioning 0?20 0?26 0?14 0?35* 0?17 70?15
Role—Physical 0?16 0?22 0?24 0?20 0?05 0?10
Bodily Pain 0?23 70?08 0?15 0?03 0?33 70?15
General health 0?18 0?15 0?28 0?25 70?02 70?01
Role—emotional 0?16 0?10 0?28 70?09 0?01 0?33
Social functioning 0?10 0?09 0?26 0?18 70?13 70?19
Vitality 0?18 0?02 0?36* 0?24 70?05 70?24
Mental health 0?15 0?09 0?34 0?07 70?02 0?13
RQLQ: Modified Asthma Quality of Life Questionnaire; SF-36: Medical Outcomes Study Short Form 36.
*P50?05; {P50?01
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Fig. 1. Correlations of HRQL with PaO2 in patients with
mild disease generally were lower and not significant (Table
2). Associations between dimensions of HRQL and PaCO2
were low and not significant in both severity categories,
except for the SF-36 physical functioning scale in moderate/
severe COPD (Table 2).
In moderate/severe COPD (ATS stage II/III) there was a
dierence in HRQL between patients with low PaO2
compared with high PaO2, using the median value as cut-
o value. These dierences were in the expected directions,but were only statistically significant in two of the RQLQ
dimensions (Table 3). In mild COPD (ATS stage I), the
dierences were of changing directions among HRQL
dimensions and were not significant (Table 3).
In a multiple linear regression model in patients with
moderate/severe disease, using the global dimension of the
lung-specific questionniare (RQLQ total) as the dependent
variable, PaO2 remained significant as an explanatory
variable after adjusting for age and gender (Table 4). This
regression model explained 28% of the variability in the
RQLQ total dimension.
FIG. 1. Arterial oxygen tension and scores in dimensions of the respiratory Quality of Life Questionnaire (0–10 scale, with 0
as maximal health) in patients with FEV1 (%pred) 5 50 (n=32–34): (a) concerns, (b) mood, (c) social, (d) total.
TABLE 3. Health-related quality of life scores in groups categorized after ATS COPD staging and below/above median arterial
PO2 in the respective groups
Moderate/severe
FEV1 (%pred) 5 50
Mild
FEV1 (%pred)=50–70
Measure PaO29?05 (n=17) PaO249?05 (n=17) P* PaO29?50 (n=15) PaO249?50 (n=10) P*
RQLQ
Breathlessness 5?9 (2?4) 5?5 (2?4){ NS 3?8 (2?0) 3?9 (2?0) NS
Concerns 6?1 (2?7) 4?4 (2?3) 0?04 3?5 (2?4) 4?4 (1?7) NS
Mood 4?5 (2?5) 3?2 (2?3) { NS 3?6 (2?4) } 4?4 (2?6) k NS
Social 6?3 (2?7) 4?5 (2?4) 0?04 2?9 (2?2) 4?0 (1?6) NS
Total 5?8 (2?3) 4?7 (2?2) { NS 3?6 (2?2)} 4?0 (1?6)k NS
SF-36
Physical functioning 45 (23) 52 (21) NS 70 (18) 76 (20) NS
Role—physical 20 (31) 29 (28) NS 45 (37) 45 (42) NS
Bodily pain 63 (31) 67 (24) NS 58 (25) 71 (33) NS
General health 34 (16) 44 (24) NS 50 (30) 41 (17) NS
Role—emotional 46 (35) 61 (40) NS 67 (36) 53 (45) NS
Social functioning 66 (28) 79 (21) NS 84 (17) 75 (26) NS
Vitality 48 (22) 57 (16) NS 47 (25) 45 (25) NS
Mental health 70 (26) 82 (16) NS 73 (19) 72 (17) NS
Results are given as means (SD).
RQLQ: Modified Asthma Quality of Life Questionnaire; SF-36: Medical Outcomes Study Short Form 36. NS: not significant.
*Mann–Whitney U-test; {n=16; {n=15; }n=14; kn=9.
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TABLE 4. Association of arterial PO2 with RQLQ total scale in patients with moderate/severe COPD (ATS staging), adjusted
for age and gender [Multiple linear regression (n=32)]
Coecient (B) Standard error 95% CI t P
Constant 1?15 4?56 78?2 to 10?5 0?25 NS
PaO2 70?55 0?24 71?04 to 70?06 72?28 0?03
Gender (dummy, male=1) 71?62 0?73 73?12 to 70?11 72?21 0?04
Age 0?06 0?06 0?04 to 0?30 0?63 0?01
RQLQ: Modified Asthma Quality of Life Questionnaire; 95% CI; 95 % confidence interval; NS: not significant.
Adjusted R2=0?28.
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We found a moderate association between PaO2 and HRQL
scores in moderately to severely aected COPD patients,
but not in patients with mild disease. This association was
higher with the lung-specific quality of life measure RQLQ,
than with the general health measure SF-36.
This suggests that there is an advantage of using a lung-
specific questionnaire over a generic health status ques-
tionnaire only when the lung function is poor. The RQLQ
contains items on respiratory symptoms, functions and
feelings. In mild COPD the questions might not be very
sensitive in detecting the reduction in health. As the disease
progresses, scores on several items might change simulta-
neously, leading to increased sensitivity when above a
minimum level of dysfunction, or a threshold. Another
possible explanation is a lower variability in PaO2 among
patients with mild disease, which might lead to a poor
association with HRQL.
The association between HRQL and PaO2 in this study
was higher than in early negative studies administering
mainly general health measures, such as the Quality of Well
Being scale (2) or the Sickness Impact Profile (SIP) (3,4).
Recently a higher association between degree of hypox-
aemia and HRQL scores was reported in COPD out-
patients with FEV1 5 1?5 1, when using a 50-item
questionnaire specifically designed for patients with airflow
limitations (St. George’s Respiratory Questionnaire=
SGRQ) (7,22). This association was higher than with the
136-item SIP (7,23). The higher correlation than reported
earlier was attributed to the lung specific nature of the
SQRQ (7).
Our subjects were younger and had better arterial blood
gas values than the subjects in the U.K. study (7), in which
patient selection procedures were not described in detail. In
the present study, patients were sampled from the total
outpatient population of COPD patients, and were
representative of outpatients with COPD. We used arterial
samples from the radial artery, compared to an arterialized
earlobe technique in the U.K. Study (7). It is suggested that
the latter technique underestimates arterial PO2 both at rest
and during exercise (8,24,25). The RQLQ total scale was
associated with arterial PO2 after adjusting for age and
gender.The questionnaires used in our study were shorter than
measures used in previous studies (20 and 36 items), hence
having a lower respondent burden. This is an advantage for
the routine use of HRQL questionnaires. The finding of
only a moderate association between PaO2 and HRQL
suggests that information obtained from HRQL measures
are useful and complementary to the usual indicators of
COPD.
In conclusion, we found a significant association between
PaO2 and HRQL scores in moderately to severely aected
COPD patients when using a short lung-specific question-
naire, in contrast to a short general health measure. The
association was higher in advanced than in mild COPD.
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